Accessibility Menu
Avalon GloboCare logo

Avalon GloboCare(NASDAQ) AVCO

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-100%
5 Year-100%
1 Year-93%
1 Month-25%
N/A
Avalon GloboCare last closing stock price
MetricPriceDate
Last closeUSD 2.892026-08-31
Avalon GloboCare stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-17.14%USD 3.492026-08-24
1 month-24.58%USD 3.832026-07-31
3 month-60.8%USD 7.372026-06-02
Year to date-87.96%USD 24.002025-12-31
1 year-92.85%USD 40.402025-08-29
3 year-99.04%USD 300.002023-09-01
5 year-99.91%USD 3,090.002021-09-01
Since inception-99.86%USD 2,100.002016-12-06

Avalon GloboCare Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$8.13M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

N/A

AVCO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Avalon GloboCare

Avalon helps people track their diet and create videos using artificial intelligence. Its Keto Air device measures body ketosis for those on special diets. The company also offers a platform that makes short videos for content creators.

Products and Services

  • Keto Air Breathalyzer: Non-invasive device for measuring ketosis, mainly for dieters; the product has generated minimal revenue to date.
  • AI Nutritionist App: Software that works with Keto Air to help users manage their diet.
  • Avalon Quantum AI Platform: AI tool that creates short-form videos for podcasters and marketers; no significant revenue yet.
  • Legacy Laboratory Services: Previously offered lab testing; exited this business in February 2025.
  • Cellular Therapy Patents: Holds patents in cell therapy and protein design; not currently developing these products.

Growth and Expansion

  • Acquired RPM Interactive in December 2025 to launch the AI video platform.
  • Formed partnerships with MIT, Arbele, and the University of Natural Resources and Life Sciences (Vienna) for technology development.
  • Exited laboratory services in February 2025 and sold real estate assets in February 2026.
  • Expanded AI platform to target more content creators, with broader rollout planned for 2026.
  • Discontinued development of a THC breathalyzer due to funding limits.

What Makes Avalon Stand Out

Avalon holds exclusive rights to distribute the Keto Air device in North America. Its AI platform automates video creation, reducing time and effort for users. The company maintains a patent portfolio and leverages partnerships for technology development.

Five Things You Need to Know

  • Revenue was $350,099 in QQ3 2025, up 1.4% from QQ3 2024.
  • Net loss was $18,260,976 in 2025, up 131.1% from 2024.
  • Cash balance was $109,091 at December 31, 2025, down 95.9% year-over-year.
  • Operating expenses doubled to $8.0 million in 2025 from $4.0 million in 2024.
  • Company has only two full-time employees as of March 25, 2026.

Bottom Line

Avalon has shifted from real estate and lab services to health tech and AI content tools. The company faces ongoing losses but continues to adapt its business model.

AI Generated • Apr 16, 2026

Industry

Real Estate Management and Development

Sector

Real Estate

Employees

2

CEO

Meng Li

Website

www.avalon-globocare.com

Headquarters

Freehold, NJ 07728, US

AVCO Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-135.36%

Return on Capital

-82.19%

Return on Assets

-60.99%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-$1.13M

Operating Income

-$12.53M

EBITDA

-$9.51M

Operating Cash Flow

-$5.11M

Capital Expenditure

-$12.16K

Free Cash Flow

-$5.12M

Cash & ST Invst.

$39.22K

Total Debt

$146.06K

Avalon GloboCare Performance Analysis

Avalon GloboCare annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 1,202,169-13.6%
20232023-12-31USD 1,255,6814.5%
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Avalon GloboCare sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Avalon GloboCare annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -19.1919.5%
20232023-12-31USD -23.8024.1%
20242024-12-31USD -8.35-64.9%
20252025-12-31USD -5.65-32.3%
Avalon GloboCare sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3099.0%
Q42025-12-31-583.3%
Q12026-03-31-22.0%
Q22026-06-3072.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$563.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

5

N/A

Net Income

-$2.18M

+83.8%

EBITDA

-$2.05M

+83.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$39.22K

-80.5%

Total Debt

$146.06K

+39.6%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$56.22K

+60.5%

Short Term Debt

$89.83K

+29.1%

Return on Assets

-60.99%

N/A

Return on Invested Capital

-82.15%

N/A

Free Cash Flow

-$707.83K

+42.3%

Operating Cash Flow

-$695.68K

+43.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GGEIGreen Giant Inc.
$0.00+0.00%
MDJHMDJM Ltd
$0.16N/A
SFRTAppreciate Holdings, Inc.
$0.00+0.00%
LSEALandsea Homes Corporation
$11.31+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$219.72-0.00%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.36-0.06%
INTCIntel
$88.83-0.01%
BIAFbioAffinity Technologies
$6.37+0.40%

Questions About AVCO

What is the current price of Avalon GloboCare?

Avalon GloboCare is trading at N/A per share.

What is the 52-week range for Avalon GloboCare?

Over the past 52 weeks, Avalon GloboCare has traded between N/A and N/A.

How much debt does Avalon GloboCare have?

As of the most recent reporting period, Avalon GloboCare reported total debt of $1.33M.

How much cash does Avalon GloboCare have on hand?

Avalon GloboCare reported $39.22K in cash and cash equivalents in its most recent financial results.

What is Avalon GloboCare’s dividend yield?

Avalon GloboCare does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services